
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4384639/publications.pdf Version: 2024-02-01



RDAD ROEVE

#	Article	IF	CITATIONS
1	Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium. Neurology, 2005, 65, 1863-1872.	1.5	4,604
2	Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS. Neuron, 2011, 72, 245-256.	3.8	4,176
3	Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain, 2011, 134, 2456-2477.	3.7	3,913
4	Diagnosis and management of dementia with Lewy bodies. Neurology, 2017, 89, 88-100.	1.5	2,805
5	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	9.4	1,962
6	Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature, 2006, 442, 916-919.	13.7	1,816
7	Mild Cognitive Impairment. Archives of Neurology, 2009, 66, 1447-55.	4.9	1,160
8	Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain, 2009, 132, 1355-1365.	3.7	975
9	11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain, 2008, 131, 665-680.	3.7	819
10	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	9.4	783
11	Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series. Sleep Medicine, 2013, 14, 744-748.	0.8	688
12	Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. Brain, 2019, 142, 744-759.	3.7	636
13	Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain, 2006, 129, 1385-1398.	3.7	624
14	The Mayo Clinic Study of Aging: Design and Sampling, Participation, Baseline Measures and Sample Characteristics. Neuroepidemiology, 2008, 30, 58-69.	1.1	623
15	Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Movement Disorders, 2001, 16, 622-630.	2.2	587
16	REM sleep behavior disorder. Annals of the New York Academy of Sciences, 2010, 1184, 15-54.	1.8	531
17	Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Human Molecular Genetics, 2006, 15, 2988-3001.	1.4	529
18	An operational approach to National Institute on Aging–Alzheimer's Association criteria for preclinical Alzheimer disease. Annals of Neurology, 2012, 71, 765-775.	2.8	520

#	Article	IF	CITATIONS
19	Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Annals of Neurology, 2003, 54, S15-S19.	2.8	496
20	Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nature Genetics, 2010, 42, 234-239.	9.4	479
21	Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. Annals of Neurology, 2018, 83, 166-177.	2.8	479
22	Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration. Nature Medicine, 2020, 26, 387-397.	15.2	471
23	Steroid-Responsive Encephalopathy Associated With Autoimmune Thyroiditis. Archives of Neurology, 2006, 63, 197.	4.9	470
24	Consensus classification of posterior cortical atrophy. Alzheimer's and Dementia, 2017, 13, 870-884.	0.4	423
25	Lewy body dementias. Lancet, The, 2015, 386, 1683-1697.	6.3	422
26	Cascading network failure across the Alzheimer's disease spectrum. Brain, 2016, 139, 547-562.	3.7	401
27	Novel Mutations in TARDBP (TDP-43) in Patients with Familial Amyotrophic Lateral Sclerosis. PLoS Genetics, 2008, 4, e1000193.	1.5	393
28	An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathologica Communications, 2016, 4, 58.	2.4	388
29	Non-Stationarity in the "Resting Brain's―Modular Architecture. PLoS ONE, 2012, 7, e39731.	1.1	382
30	Neuropathologic Outcome of Mild Cognitive Impairment Following Progression to Clinical Dementia. Archives of Neurology, 2006, 63, 674.	4.9	377
31	Parkinson Disease Neuropathology. Archives of Neurology, 2002, 59, 102.	4.9	366
32	Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology, 2020, 94, 743-755.	1.5	365
33	Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Medicine, 2003, 4, 281-284.	0.8	364
34	Invited review: Frontotemporal dementia caused by <i>microtubuleâ€associated protein tau</i> gene ( <scp><i>MAPT</i></scp> ) mutations: a chameleon for neuropathology and neuroimaging. Neuropathology and Applied Neurobiology, 2015, 41, 24-46.	1.8	360
35	Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. Brain, 2012, 135, 794-806.	3.7	355
36	Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study. Lancet Neurology, The, 2012, 11, 868-877.	4.9	355

#	Article	IF	CITATIONS
37	Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. Brain, 2008, 131, 2957-2968.	3.7	354
38	Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. Brain, 2009, 132, 583-591.	3.7	344
39	TDP-43 is a key player in the clinical features associated with Alzheimer's disease. Acta Neuropathologica, 2014, 127, 811-824.	3.9	336
40	Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain, 2012, 135, 765-783.	3.7	322
41	Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurology, The, 2014, 13, 686-699.	4.9	302
42	REM sleep behaviour disorder. Nature Reviews Disease Primers, 2018, 4, 19.	18.1	290
43	Discovery of a Biomarker and Lead Small Molecules to Target r(GGGGCC)-Associated Defects in c9FTD/ALS. Neuron, 2014, 83, 1043-1050.	3.8	289
44	Association of traumatic brain injury with subsequent neurological and psychiatric disease: a meta-analysis. Journal of Neurosurgery, 2016, 124, 511-526.	0.9	280
45	Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia: a cluster analysis study. Brain, 2009, 132, 2932-2946.	3.7	277
46	Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Human Molecular Genetics, 2008, 17, 3631-3642.	1.4	271
47	Incidence of Dementia With Lewy Bodies and Parkinson Disease Dementia. JAMA Neurology, 2013, 70, 1396.	4.5	250
48	Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in an aging and dementia cohort. Sleep Medicine, 2011, 12, 445-453.	0.8	236
49	Chronic traumatic encephalopathy pathology in a neurodegenerative disorders brain bank. Acta Neuropathologica, 2015, 130, 877-889.	3.9	235
50	REM Sleep Behavior Disorder in Parkinson's Disease and Dementia with Lewy Bodies. Journal of Geriatric Psychiatry and Neurology, 2004, 17, 146-157.	1.2	229
51	Voxel-based morphometry in autopsy proven PSP and CBD. Neurobiology of Aging, 2008, 29, 280-289.	1.5	221
52	Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurology, The, 2021, 20, 739-752.	4.9	220
53	Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia. Brain, 2018, 141, 271-287.	3.7	218
54	Mild cognitive impairment due to Alzheimer disease in the community. Annals of Neurology, 2013, 74, 199-208.	2.8	215

#	Article	IF	CITATIONS
55	Occurrence and clinical correlates of REM sleep behaviour disorder in patients with Parkinson's disease over time. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 387-391.	0.9	211
56	Depression, Apolipoprotein E Genotype, and the Incidence of Mild Cognitive Impairment. Archives of Neurology, 2006, 63, 435.	4.9	206
57	Treatment outcomes in REM sleep behavior disorder. Sleep Medicine, 2013, 14, 237-242.	0.8	202
58	Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C→T (Arg493X) mutation: an international initiative. Lancet Neurology, The, 2007, 6, 857-868.	4.9	199
59	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303.	9.4	198
60	Mild cognitive impairment associated with limbic and neocortical lewy body disease: a clinicopathological study. Brain, 2010, 133, 540-556.	3.7	195
61	TDP-43 represses cryptic exon inclusion in the FTD–ALS gene UNC13A. Nature, 2022, 603, 124-130.	13.7	193
62	Nonamnestic mild cognitive impairment progresses to dementia with Lewy bodies. Neurology, 2013, 81, 2032-2038.	1.5	191
63	Essentials of the Proper Diagnoses of Mild Cognitive Impairment, Dementia, and Major Subtypes of Dementia. Mayo Clinic Proceedings, 2003, 78, 1290-1308.	1.4	187
64	Neuropathologic Features of Frontotemporal Lobar Degeneration With Ubiquitin-Positive Inclusions With Progranulin Gene (PGRN) Mutations. Journal of Neuropathology and Experimental Neurology, 2007, 66, 142-151.	0.9	184
65	Comparison of <sup>18</sup> F-FDG and PiB PET in Cognitive Impairment. Journal of Nuclear Medicine, 2009, 50, 878-886.	2.8	183
66	Antemortem diagnosis of frontotemporal lobar degeneration. Annals of Neurology, 2005, 57, 480-488.	2.8	181
67	Probable rapid eye movement sleep behavior disorder increases risk for mild cognitive impairment and Parkinson disease: A populationâ€based study. Annals of Neurology, 2012, 71, 49-56.	2.8	179
68	Imaging correlates of posterior cortical atrophy. Neurobiology of Aging, 2007, 28, 1051-1061.	1.5	176
69	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurology, The, 2020, 19, 145-156.	4.9	175
70	CCNF mutations in amyotrophic lateral sclerosis and frontotemporal dementia. Nature Communications, 2016, 7, 11253.	5.8	174
71	Neuropsychological Differentiation of Dementia with Lewy Bodies from Normal Aging and Alzheimer's Disease. Clinical Neuropsychologist, 2006, 20, 623-636.	1.5	170
72	Clinical, neuroimaging and neuropathological features of a new chromosome 9p-linked FTD-ALS family. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 196-203.	0.9	170

#	Article	IF	CITATIONS
73	Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. Nature Communications, 2015, 6, 7247.	5.8	170
74	Prominent phenotypic variability associated with mutations in Progranulin. Neurobiology of Aging, 2009, 30, 739-751.	1.5	166
75	Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease. JAMA Neurology, 2014, 71, 1394.	4.5	166
76	Idiopathic REM sleep behaviour disorder in the development of Parkinson's disease. Lancet Neurology, The, 2013, 12, 469-482.	4.9	164
77	Basal ganglia T1 hyperintensity in LGI1-autoantibody faciobrachial dystonic seizures. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e161.	3.1	163
78	Refining Frontotemporal Dementia With Parkinsonism Linked to Chromosome 17. Archives of Neurology, 2008, 65, 460.	4.9	162
79	Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiology of Aging, 2012, 33, 2091-2105.	1.5	162
80	Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum. Cortex, 2017, 97, 143-159.	1.1	162
81	Comparison of the Short Test of Mental Status and the Mini-Mental State Examination in Mild Cognitive Impairment. Archives of Neurology, 2003, 60, 1777.	4.9	158
82	Autoimmune Dementia: Clinical Course and Predictors of Immunotherapy Response. Mayo Clinic Proceedings, 2010, 85, 881-897.	1.4	158
83	White-matter integrity on DTI and the pathologic staging of Alzheimer's disease. Neurobiology of Aging, 2017, 56, 172-179.	1.5	158
84	Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders. Brain, 2020, 143, 1632-1650.	3.7	158
85	Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage. NeuroImage, 2008, 42, 559-567.	2.1	152
86	AVâ€1451 tau and βâ€amyloid positron emission tomography imaging in dementia with Lewy bodies. Annals of Neurology, 2017, 81, 58-67.	2.8	152
87	Autoimmune Encephalopathies. Neurologist, 2007, 13, 140-147.	0.4	150
88	Association of Excessive Daytime Sleepiness With Longitudinal β-Amyloid Accumulation in Elderly Persons Without Dementia. JAMA Neurology, 2018, 75, 672.	4.5	150
89	Melatonin therapy for REM sleep behavior disorder: a critical review of evidence. Sleep Medicine, 2015, 16, 19-26.	0.8	149
90	Rates of cerebral atrophy differ in different degenerative pathologies. Brain, 2006, 130, 1148-1158.	3.7	146

#	Article	IF	CITATIONS
91	Indicators of amyloid burden in a population-based study of cognitively normal elderly. Neurology, 2012, 79, 1570-1577.	1.5	146
92	Dementia with Lewy bodies. Neurology, 2014, 83, 801-809.	1.5	143
93	REM Sleep Behavior Disorder: Diagnosis, Clinical Implications, and Future Directions. Mayo Clinic Proceedings, 2017, 92, 1723-1736.	1.4	143
94	Association of diabetes with amnestic and nonamnestic mild cognitiveÂimpairment. Alzheimer's and Dementia, 2014, 10, 18-26.	0.4	141
95	<scp>REM</scp> <scp>S</scp> leep <scp>B</scp> ehavior <scp>D</scp> isorder in <scp>P</scp> arkinson's <scp>D</scp> isease and <scp>O</scp> ther <scp>S</scp> ynucleinopathies. Movement Disorders, 2017, 32, 645-658.	2.2	139
96	Validation of the Neuropathologic Criteria of the Third Consortium for Dementia With Lewy Bodies for Prospectively Diagnosed Cases. Journal of Neuropathology and Experimental Neurology, 2008, 67, 649-656.	0.9	137
97	Incidental Lewy body disease: Do some cases represent a preclinical stage of dementia with Lewy bodies?. Neurobiology of Aging, 2011, 32, 857-863.	1.5	136
98	Positron Emission Tomography–Computed Tomography in Paraneoplastic Neurologic Disorders. Archives of Neurology, 2010, 67, 322.	4.9	131
99	EEG findings in steroid-responsive encephalopathy associated with autoimmune thyroiditis. Clinical Neurophysiology, 2003, 114, 32-37.	0.7	130
100	Atypical Progressive Supranuclear Palsy With Corticospinal Tract Degeneration. Journal of Neuropathology and Experimental Neurology, 2006, 65, 396-405.	0.9	129
101	The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes. Brain, 2019, 142, 3230-3242.	3.7	129
102	Validation of the Mayo Sleep Questionnaire to Screen for REM Sleep Behavior Disorder in a Community-Based Sample. Journal of Clinical Sleep Medicine, 2013, 09, 475-480.	1.4	128
103	Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART). Acta Neuropathologica, 2017, 133, 705-715.	3.9	125
104	Dementia with Lewy bodies may present as dementia and REM sleep behavior disorder without parkinsonism or hallucinations. Journal of the International Neuropsychological Society, 2002, 8, 907-914.	1.2	124
105	Practice Effects and Longitudinal Cognitive Change in Normal Aging vs. Incident Mild Cognitive Impairment and Dementia in The Mayo Clinic Study of Aging. Clinical Neuropsychologist, 2013, 27, 1247-1264.	1.5	124
106	<i>APOE</i> ε4 is associated with severity of Lewy body pathology independent of Alzheimer pathology. Neurology, 2018, 91, e1182-e1195.	1.5	122
107	Neuropathological features of corticobasal degeneration presenting as corticobasal syndrome or Richardson syndrome. Brain, 2011, 134, 3264-3275.	3.7	119
108	Early Alzheimer's Disease Neuropathology Detected by Proton MR Spectroscopy. Journal of Neuroscience, 2014, 34, 16247-16255.	1.7	117

#	Article	IF	CITATIONS
109	Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia. Journal of Clinical Investigation, 2020, 130, 6080-6092.	3.9	117
110	Spt4 selectively regulates the expression of <i>C9orf72</i> sense and antisense mutant transcripts. Science, 2016, 353, 708-712.	6.0	116
111	Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder. Lancet Neurology, The, 2021, 20, 671-684.	4.9	116
112	The chromosome 9 ALS and FTD locus is probably derived from a single founder. Neurobiology of Aging, 2012, 33, 209.e3-209.e8.	1.5	115
113	Young-Onset Dementia. Archives of Neurology, 2008, 65, 1502.	4.9	113
114	Pattern of brain atrophy rates in autopsy-confirmed dementia with Lewy bodies. Neurobiology of Aging, 2015, 36, 452-461.	1.5	113
115	Tauâ€positron emission tomography correlates with neuropathology findings. Alzheimer's and Dementia, 2020, 16, 561-571.	0.4	113
116	Frequency and Correlates of Caregiverâ€Reported Sleep Disturbances in a Sample of Persons with Early Dementia. Journal of the American Geriatrics Society, 2010, 58, 480-486.	1.3	112
117	Increased tau burden in the cortices of progressive supranuclear palsy presenting with corticobasal syndrome. Movement Disorders, 2005, 20, 982-988.	2.2	111
118	18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons. Neurobiology of Aging, 2014, 35, 2096-2106.	1.5	108
119	REM Sleep Behavior Disorder and REM Sleep Without Atonia as an Early Manifestation of Degenerative Neurological Disease. Current Neurology and Neuroscience Reports, 2012, 12, 182-192.	2.0	106
120	Frontotemporal dementia and parkinsonism associated with the IVS1+1G->A mutation in progranulin: a clinicopathologic study. Brain, 2006, 129, 3103-3114.	3.7	105
121	Alzheimer's disease and corticobasal degeneration presenting as corticobasal syndrome. Movement Disorders, 2009, 24, 1375-1379.	2.2	105
122	Temporoparietal atrophy: A marker of AD pathology independent of clinical diagnosis. Neurobiology of Aging, 2011, 32, 1531-1541.	1.5	105
123	Diagnostic Thresholds for Quantitative REM Sleep Phasic Burst Duration, Phasic and Tonic Muscle Activity, and REM Atonia Index in REM Sleep Behavior Disorder with and without Comorbid Obstructive Sleep Apnea. Sleep, 2014, 37, 1649-1662.	0.6	105
124	Novel clinical associations with specific C9ORF72 transcripts in patients with repeat expansions in C9ORF72. Acta Neuropathologica, 2015, 130, 863-876.	3.9	104
125	REM sleep behavior disorder initiated by acute brainstem multiple sclerosis. Neurology, 2006, 66, 1277-1279.	1.5	102
126	Shapes of the Trajectories of 5 Major Biomarkers of Alzheimer Disease. Archives of Neurology, 2012, 69, 856-67.	4.9	99

#	Article	IF	CITATIONS
127	Rapid eye movement sleep behavior disorder and subtypes in autopsyâ€confirmed dementia with Lewy bodies. Movement Disorders, 2012, 27, 72-78.	2.2	99
128	Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy. Movement Disorders, 2019, 34, 1144-1153.	2.2	98
129	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurology, The, 2018, 17, 548-558.	4.9	97
130	Rescue of a lysosomal storage disorder caused by Grn loss of function with a brain penetrant progranulin biologic. Cell, 2021, 184, 4651-4668.e25.	13.5	97
131	Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 862-871.	0.4	93
132	A Presenilin 1 Mutation Associated with Familial Frontotemporal Dementia Inhibits Î <sup>3</sup> -Secretase Cleavage of APP and Notch. Neurobiology of Disease, 2002, 9, 269-273.	2.1	92
133	C9orf72 Hexanucleotide Repeat Expansions in Clinical Alzheimer Disease. JAMA Neurology, 2013, 70, 736.	4.5	92
134	Mutations in progranulin explain atypical phenotypes with variants in MAPT. Brain, 2006, 129, 3124-3126.	3.7	91
135	Focal atrophy on MRI and neuropathologic classification of dementia with Lewy bodies. Neurology, 2012, 79, 553-560.	1.5	91
136	Antemortem differential diagnosis of dementia pathology using structural MRI: Differential-STAND. NeuroImage, 2011, 55, 522-531.	2.1	90
137	Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. Acta Neuropathologica, 2019, 137, 879-899.	3.9	90
138	Cerebellar c9RAN proteins associate with clinical and neuropathological characteristics of C9ORF72 repeat expansion carriers. Acta Neuropathologica, 2015, 130, 559-573.	3.9	89
139	A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. Acta Neuropathologica, 2019, 138, 237-250.	3.9	87
140	Antidepressants Increase REM Sleep Muscle Tone in Patients with and without REM Sleep Behavior Disorder. Sleep, 2015, 38, 907-17.	0.6	86
141	<i>C9ORF72</i> repeat expansions in cases with previously identified pathogenic mutations. Neurology, 2013, 81, 1332-1341.	1.5	84
142	Length of normal alleles of C9ORF72 GGGGCC repeat do not influence disease phenotype. Neurobiology of Aging, 2012, 33, 2950.e5-2950.e7.	1.5	83
143	Voxel-Based Morphometry in Frontotemporal Lobar Degeneration With Ubiquitin-Positive Inclusions With and Without Progranulin Mutations. Archives of Neurology, 2007, 64, 371.	4.9	82
144	A population-based study of the association between bullous pemphigoid and neurologic disorders. Journal of the American Academy of Dermatology, 2014, 71, 1191-1197.	0.6	81

#	Article	IF	CITATIONS
145	High School Football and Late-Life Risk of Neurodegenerative Syndromes, 1956-1970. Mayo Clinic Proceedings, 2017, 92, 66-71.	1.4	81
146	Progressive dysexecutive syndrome due to Alzheimer's disease: a description of 55 cases and comparison to other phenotypes. Brain Communications, 2020, 2, fcaa068.	1.5	81
147	Utility of the global CDR <sup>®</sup> plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium. Alzheimer's and Dementia, 2020, 16, 106-117.	0.4	81
148	Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 1005-1014.	0.4	80
149	Comparison of Gait Parameters forÂPredicting Cognitive Decline: TheÂMayoÂClinic Study of Aging. Journal of Alzheimer's Disease, 2016, 55, 559-567.	1.2	79
150	Excessive daytime sleepiness and fatigue may indicate accelerated brain aging in cognitively normal late middle-aged and older adults. Sleep Medicine, 2017, 32, 236-243.	0.8	79
151	The Multiple Phenotypes of Corticobasal Syndrome and Corticobasal Degeneration: Implications for Further Study. Journal of Molecular Neuroscience, 2011, 45, 350-353.	1.1	78
152	Factors associated with injury in REM sleep behavior disorder. Sleep Medicine, 2014, 15, 1332-1338.	0.8	78
153	<scp>Alphaâ€Synuclein</scp> Oligomers and Neurofilament Light Chain in Spinal Fluid Differentiate Multiple System Atrophy from Lewy Body Synucleinopathies. Annals of Neurology, 2020, 88, 503-512.	2.8	78
154	The Treatment of Parasomnias with Hypnosis: a 5-Year Follow-Up Study. Journal of Clinical Sleep Medicine, 2007, 03, 369-373.	1.4	77
155	Progressive Nonfluent Aphasia and Subsequent Aphasic Dementia Associated with Atypical Progressive Supranuclear Palsy Pathology. European Neurology, 2003, 49, 72-78.	0.6	76
156	Frontotemporal dementia with the V337M <i>MAPT</i> mutation. Neurology, 2017, 88, 758-766.	1.5	76
157	In-depth clinico-pathological examination of RNA foci in a large cohort of C9ORF72 expansion carriers. Acta Neuropathologica, 2017, 134, 255-269.	3.9	76
158	Sleep Disturbance in Dementia with Lewy Bodies and Alzheimer's Disease: A Multicenter Analysis. Dementia and Geriatric Cognitive Disorders, 2011, 31, 239-246.	0.7	75
159	Polysomnographic Findings in Dementia With Lewy Bodies. Neurologist, 2013, 19, 1-6.	0.4	75
160	ABI3 and PLCG2 missense variants as risk factors for neurodegenerative diseases in Caucasians and African Americans. Molecular Neurodegeneration, 2018, 13, 53.	4.4	75
161	Frontotemporal Dementia Treatment: Current Symptomatic Therapies and Implications of Recent Genetic, Biochemical, and Neuroimaging Studies. Alzheimer Disease and Associated Disorders, 2007, 21, S79-S87.	0.6	74
162	Ataxin-2 as potential disease modifier in C9ORF72 expansion carriers. Neurobiology of Aging, 2014, 35, 2421.e13-2421.e17.	1.5	74

#	Article	IF	CITATIONS
163	Predicting future rates of tau accumulation on PET. Brain, 2020, 143, 3136-3150.	3.7	74
164	Probable RBD is increased in Parkinson's disease but not in essential tremor or restless legs syndrome. Parkinsonism and Related Disorders, 2011, 17, 456-458.	1.1	73
165	Association of hypometabolism and amyloid levels in aging, normal subjects. Neurology, 2014, 82, 1959-1967.	1.5	73
166	[ <sup>18</sup> F]AVâ€1451 tauâ€PET and primary progressive aphasia. Annals of Neurology, 2018, 83, 599-611.	. 2.8	73
167	Lewy body variant of alzheimer's disease (AD) identified by postmortem ubiquitin staining in a previously reported case of AD associated with REM sleep behavior disorder. Biological Psychiatry, 1997, 42, 527-528.	0.7	71
168	Anatomical differences between CBSâ€corticobasal degeneration and CBSâ€Alzheimer's disease. Movement Disorders, 2010, 25, 1246-1252.	2.2	71
169	Mild cognitive impairment in the oldest old. Neurology, 2003, 60, 477-480.	1.5	70
170	Involvement of medullary regions controlling sympathetic output in Lewy body disease. Brain, 2004, 128, 338-344.	3.7	70
171	Progranulin protein levels are differently regulated in plasma and CSF. Neurology, 2014, 82, 1871-1878.	1.5	70
172	Ante mortem amyloid imaging and $\hat{l}^2$ -amyloid pathology in a case with dementia with Lewy bodies. Neurobiology of Aging, 2012, 33, 878-885.	1.5	69
173	TYROBP genetic variants in early-onset Alzheimer's disease. Neurobiology of Aging, 2016, 48, 222.e9-222.e15.	1.5	69
174	When Do α-Synucleinopathies Start? An Epidemiological Timeline. JAMA Neurology, 2018, 75, 503.	4.5	69
175	The limbic and neocortical contribution of $\hat{l}\pm\hat{a}\in s$ ynuclein, tau, and amyloid $\hat{l}^2$ to disease duration in dementia with Lewy bodies. Alzheimer's and Dementia, 2018, 14, 330-339.	0.4	69
176	REM sleep behavior disorder: A possible early marker for synucleinopathies. Neurology, 2006, 66, 796-797.	1.5	68
177	Amyloid-β deposition and regional grey matter atrophy rates in dementia with Lewy bodies. Brain, 2016, 139, 2740-2750.	3.7	68
178	Survival and Causes of Death Among People With Clinically Diagnosed Synucleinopathies With Parkinsonism. JAMA Neurology, 2017, 74, 839.	4.5	68
179	MR Elastography Demonstrates Unique Regional Brain Stiffness Patterns in Dementias. American Journal of Roentgenology, 2017, 209, 403-408.	1.0	68
180	Predictors of neural-specific autoantibodies and immunotherapy response in patients with cognitive dysfunction. Journal of Neuroimmunology, 2018, 323, 62-72.	1.1	68

#	Article	IF	CITATIONS
181	Entorhinal cortex tau, amyloid- $\hat{l}^2$ , cortical thickness and memory performance in non-demented subjects. Brain, 2019, 142, 1148-1160.	3.7	68
182	Dopaminergic imaging and clinical predictors for phenoconversion of REM sleep behaviour disorder. Brain, 2021, 144, 278-287.	3.7	68
183	Correlation Between Antemortem Magnetic Resonance Imaging Findings and Pathologically Confirmed Corticobasal Degeneration. Archives of Neurology, 2004, 61, 1881-4.	4.9	67
184	Spectrum of cognition short of dementia. Neurology, 2015, 85, 1712-1721.	1.5	67
185	[ <sup>18</sup> F]AVâ€1451 clustering of entorhinal and cortical uptake in Alzheimer's disease. Annals of Neurology, 2018, 83, 248-257.	2.8	67
186	FDG-PET in tau-negative amnestic dementia resembles that of autopsy-proven hippocampal sclerosis. Brain, 2018, 141, 1201-1217.	3.7	67
187	Clinically Undetected Motor Neuron Disease in Pathologically Proven Frontotemporal Lobar Degeneration With Motor Neuron Disease. Archives of Neurology, 2006, 63, 506.	4.9	66
188	Association between contact sports participation and chronic traumatic encephalopathy: a retrospective cohort study. Brain Pathology, 2020, 30, 63-74.	2.1	66
189	Links Between Frontotemporal Lobar Degeneration, Corticobasal Degeneration, Progressive Supranuclear Palsy, and Amyotrophic Lateral Sclerosis. Alzheimer Disease and Associated Disorders, 2007, 21, S31-S38.	0.6	65
190	Longitudinal multimodal imaging and clinical endpoints for frontotemporal dementia clinical trials. Brain, 2019, 142, 443-459.	3.7	65
191	β-Amyloid PET and neuropathology in dementia with Lewy bodies. Neurology, 2020, 94, e282-e291.	1.5	65
192	Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies. Brain, 2012, 135, 2470-2477.	3.7	64
193	Genetic modifiers in carriers of repeat expansions in the C9ORF72 gene. Molecular Neurodegeneration, 2014, 9, 38.	4.4	63
194	Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers. NeuroImage, 2021, 224, 117433.	2.1	63
195	Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations. Lancet Neurology, The, 2022, 21, 258-272.	4.9	63
196	A Comprehensive Resource for Induced Pluripotent Stem Cells from Patients with Primary Tauopathies. Stem Cell Reports, 2019, 13, 939-955.	2.3	62
197	Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults. Neurology, 2019, 93, e29-e39.	1.5	62
198	β-Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies. Neurology, 2020, 95, e3257-e3268.	1.5	62

#	Article	IF	CITATIONS
199	Imaging Signatures of Molecular Pathology in Behavioral Variant Frontotemporal Dementia. Journal of Molecular Neuroscience, 2011, 45, 372-8.	1.1	61
200	Risk and protective factors for cognitive impairment in persons aged 85 years and older. Neurology, 2015, 84, 1854-1861.	1.5	61
201	In vivo <sup>18</sup> F-AV-1451 tau PET signal in <i>MAPT</i> mutation carriers varies by expected tau isoforms. Neurology, 2018, 90, e947-e954.	1.5	60
202	Association of Apolipoprotein E ε4 With Transactive Response DNA-Binding Protein 43. JAMA Neurology, 2018, 75, 1347.	4.5	60
203	Dementia with Lewy Bodies. Neurologic Clinics, 2007, 25, 741-760.	0.8	59
204	Alzheimer Disease–like Phenotype Associated With the c.154delA Mutation in Progranulin. Archives of Neurology, 2010, 67, 171-7.	4.9	59
205	Diagnostic REM sleep muscle activity thresholds in patients with idiopathic REM sleep behavior disorder with and without obstructive sleep apnea. Sleep Medicine, 2017, 33, 23-29.	0.8	59
206	Polygenic risk scores in familial Alzheimer disease. Neurology, 2017, 88, 1180-1186.	1.5	59
207	Corticobasal degeneration with TDP-43 pathology presenting with progressive supranuclear palsy syndrome: a distinct clinicopathologic subtype. Acta Neuropathologica, 2018, 136, 389-404.	3.9	59
208	MRI and pathology of REM sleep behavior disorder in dementia with Lewy bodies. Neurology, 2013, 81, 1681-1689.	1.5	58
209	Sleep Disturbances in Frontotemporal Dementia. Current Neurology and Neuroscience Reports, 2016, 16, 85.	2.0	57
210	Symmetric corticobasal degeneration (S-CBD). Parkinsonism and Related Disorders, 2010, 16, 208-214.	1.1	56
211	Magnetic resonance elastography of frontotemporal dementia. Journal of Magnetic Resonance Imaging, 2016, 43, 474-478.	1.9	56
212	Longitudinal characterization of two siblings with frontotemporal dementia and parkinsonism linked to chromosome 17 associated with the S305N tau mutation. Brain, 2005, 128, 752-772.	3.7	55
213	Neuropsychological assessment of patients with dementing illness. Nature Reviews Neurology, 2011, 7, 677-687.	4.9	55
214	Arguing against the proposed definition changes of PD. Movement Disorders, 2016, 31, 1619-1622.	2.2	55
215	Subtle gait changes in patients with REM sleep behavior disorder. Movement Disorders, 2013, 28, 1847-1853.	2.2	53
216	Depressive and anxiety symptoms and cortical amyloid deposition among cognitively normal elderly persons: the Mayo Clinic Study of Aging. International Psychogeriatrics, 2018, 30, 245-251.	0.6	52

#	Article	IF	CITATIONS
217	Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration. Neurology, 2021, 96, e2296-e2312.	1.5	52
218	Deep learning-based brain age prediction in normal aging and dementia. Nature Aging, 2022, 2, 412-424.	5.3	52
219	A Preliminary Fluorodeoxyglucose Positron Emission Tomography Study in Healthy Adults Reporting Dream-Enactment Behavior. Sleep, 2006, 29, 927-933.	0.6	51
220	Mild cognitive impairment associated with underlying Alzheimer's disease versus Lewy body disease. Parkinsonism and Related Disorders, 2012, 18, S41-S44.	1.1	51
221	Mitochondrial targeting sequence variants of the <i>CHCHD2</i> gene are a risk for Lewy body disorders. Neurology, 2015, 85, 2016-2025.	1.5	51
222	Longitudinal neuroimaging biomarkers differ across Alzheimer's disease phenotypes. Brain, 2020, 143, 2281-2294.	3.7	51
223	Frontotemporal Dementia Mimicking Dementia With Lewy Bodies. Cognitive and Behavioral Neurology, 2008, 21, 157-163.	0.5	50
224	The Role of Cardiovascular Risk Factors and Stroke in Familial Alzheimer Disease. JAMA Neurology, 2016, 73, 1231.	4.5	49
225	Age-Specific Incidence Rates for Dementia and Alzheimer Disease in NIA-LOAD/NCRAD and EFIGA Families. JAMA Neurology, 2014, 71, 315.	4.5	48
226	Hypothyroidism and Risk of Mild Cognitive Impairment in Elderly Persons. JAMA Neurology, 2014, 71, 201.	4.5	48
227	Duration and Pathologic Correlates of Lewy Body Disease. JAMA Neurology, 2017, 74, 310.	4.5	48
228	Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease. Alzheimer's and Dementia, 2019, 15, 927-939.	0.4	48
229	Use of the CDR® plus NACC FTLD in mild FTLD: Data from the ARTFL/LEFFTDS consortium. Alzheimer's and Dementia, 2020, 16, 79-90.	0.4	48
230	Clinical-pathologic study of biomarkers in FTDP-17 (PPND family with N279K tau mutation). Parkinsonism and Related Disorders, 2007, 13, 230-239.	1.1	47
231	MRI Correlates of Protein Deposition and Disease Severity in Postmortem Frontotemporal Lobar Degeneration. Neurodegenerative Diseases, 2009, 6, 106-117.	0.8	47
232	Subtypes of dementia with Lewy bodies are associated with α-synuclein and tau distribution. Neurology, 2020, 95, e155-e165.	1.5	47
233	Abnormal daytime sleepiness in dementia with Lewy bodies compared to Alzheimer's disease using the Multiple Sleep Latency Test. Alzheimer's Research and Therapy, 2014, 6, 76.	3.0	45
234	Antemortem MRI findings associated with microinfarcts at autopsy. Neurology, 2014, 82, 1951-1958.	1.5	45

#	Article	IF	CITATIONS
235	Neuroimaging-evident lesional pathology associated with REM sleep behavior disorder. Sleep Medicine, 2015, 16, 1502-1510.	0.8	45
236	REM sleep muscle activity in idiopathic REM sleep behavior disorder predicts phenoconversion. Neurology, 2019, 93, e1171-e1179.	1.5	45
237	New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures. Alzheimer's and Dementia, 2020, 16, 131-143.	0.4	45
238	Protein contributions to brain atrophy acceleration in Alzheimer's disease and primary age-related tauopathy. Brain, 2020, 143, 3463-3476.	3.7	45
239	<i>GBA</i> variants in REM sleep behavior disorder. Neurology, 2020, 95, e1008-e1016.	1.5	45
240	Hippocampal volumes predict risk of dementia with Lewy bodies in mild cognitive impairment. Neurology, 2016, 87, 2317-2323.	1.5	44
241	Plasma sphingolipid changes with autopsyâ€confirmed Lewy body or Alzheimer's pathology. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 3, 43-50.	1.2	44
242	Current management of sleep disturbances in dementia. Current Neurology and Neuroscience Reports, 2002, 2, 169-177.	2.0	42
243	Rarity of the Alzheimer Disease–Protective <i>APP</i> A673T Variant in the United States. JAMA Neurology, 2015, 72, 209.	4.5	41
244	An investigation of cerebrovascular lesions in dementia with Lewy bodies compared to Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 257-266.	0.4	41
245	Lesional REM sleep behavior disorder localizes to the dorsomedial pons. Neurology, 2014, 83, 1871-1873.	1.5	40
246	Extensive transcriptomic study emphasizes importance of vesicular transport in C9orf72 expansion carriers. Acta Neuropathologica Communications, 2019, 7, 150.	2.4	40
247	Efficacy, Safety, and Tolerability of Armodafinil Therapy for Hypersomnia Associated with Dementia with Lewy Bodies: A Pilot Study. Dementia and Geriatric Cognitive Disorders, 2017, 43, 269-280.	0.7	39
248	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. Brain, 2018, 141, 2895-2907.	3.7	39
249	Association of <i>MAPT</i> Subhaplotypes With Risk of Progressive Supranuclear Palsy and Severity of Tau Pathology. JAMA Neurology, 2019, 76, 710.	4.5	39
250	Longitudinal structural and metabolic changes in frontotemporal dementia. Neurology, 2020, 95, e140-e154.	1.5	39
251	Fineâ€Mapping of <i>SNCA</i> in Rapid Eye Movement Sleep Behavior Disorder and Overt Synucleinopathies. Annals of Neurology, 2020, 87, 584-598.	2.8	39
252	Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases. Brain, 2022, 145, 27-44.	3.7	38

#	Article	IF	CITATIONS
253	Antemortem volume loss mirrors TDP-43 staging in older adults with non-frontotemporal lobar degeneration. Brain, 2019, 142, 3621-3635.	3.7	37
254	<i>APOE3</i> -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia. Science Translational Medicine, 2021, 13, eabc9375.	5.8	37
255	Parkinson-Related Dementias. Neurologic Clinics, 2007, 25, 761-781.	0.8	36
256	Restless legs syndrome and daytime sleepiness are prominent in myotonic dystrophy type 2. Neurology, 2013, 81, 157-164.	1.5	36
257	Improving clinical cognitive testing. Neurology, 2015, 85, 910-918.	1.5	36
258	White matter integrity in dementia with Lewy bodies: a voxel-based analysis of diffusion tensor imaging. Neurobiology of Aging, 2015, 36, 2010-2017.	1.5	35
259	Comparison of the Short Test of Mental Status and the Montreal Cognitive Assessment Across the Cognitive Spectrum. Mayo Clinic Proceedings, 2019, 94, 1516-1523.	1.4	35
260	Long-Term Locomotor Training for Gait and Balance in a Patient With Mixed Progressive Supranuclear Palsy and Corticobasal Degeneration. Physical Therapy, 2007, 87, 1078-1087.	1.1	34
261	Comparison of Risk Factor Profiles in Incidental Lewy Body Disease and Parkinson Disease. Archives of Neurology, 2009, 66, 1114-9.	4.9	34
262	Network-driven plasma proteomics expose molecular changes in the Alzheimer's brain. Molecular Neurodegeneration, 2016, 11, 31.	4.4	34
263	Progressive supranuclear palsy. Parkinsonism and Related Disorders, 2012, 18, S192-S194.	1.1	33
264	Tracking disease progression in familial and sporadic frontotemporal lobar degeneration: Recent findings from ARTFL and LEFFTDS. Alzheimer's and Dementia, 2020, 16, 71-78.	0.4	33
265	The strong presence of REM sleep behavior disorder in PD: Clinical and research implications. Neurology, 2011, 77, 1030-1032.	1.5	32
266	<i>MAPT</i> haplotype H1G is associated with increased risk of dementia with Lewy bodies. Alzheimer's and Dementia, 2016, 12, 1297-1304.	0.4	32
267	Predicting Survival in Dementia With Lewy Bodies With Hippocampal Volumetry. Movement Disorders, 2016, 31, 989-994.	2.2	32
268	The longitudinal evaluation of familial frontotemporal dementia subjects protocol: Framework and methodology. Alzheimer's and Dementia, 2020, 16, 22-36.	0.4	32
269	Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials. Alzheimer's Research and Therapy, 2020, 12, 137.	3.0	32
270	A computational model of neurodegeneration in Alzheimer's disease. Nature Communications, 2022, 13, 1643.	5.8	32

#	Article	IF	CITATIONS
271	Role for the microtubule-associated protein tau variant p.A152T in risk of α-synucleinopathies. Neurology, 2015, 85, 1680-1686.	1.5	31
272	Full sequencing and haplotype analysis of <i>MAPT</i> in Parkinson's disease and rapid eye movement sleep behavior disorder. Movement Disorders, 2018, 33, 1016-1020.	2.2	31
273	Regional cortical perfusion on arterial spin labeling MRI in dementia with Lewy bodies: Associations with clinical severity, glucose metabolism and tau PET. NeuroImage: Clinical, 2018, 19, 939-947.	1.4	31
274	Rates of cerebral atrophy in autopsy-confirmed progressive supranuclear palsy. Annals of Neurology, 2006, 59, 200-203.	2.8	30
275	Age and apoE associations with complex pathologic features in Alzheimer's disease. Journal of the Neurological Sciences, 2008, 273, 34-39.	0.3	30
276	What is the quality of life in the oldest old?. International Psychogeriatrics, 2011, 23, 1003-1010.	0.6	30
277	Treatment of Dementia With Lewy Bodies. Current Treatment Options in Neurology, 2013, 15, 738-764.	0.7	30
278	LRRK2 variation and dementia with Lewy bodies. Parkinsonism and Related Disorders, 2016, 31, 98-103.	1.1	30
279	Thalamo-cortical network hyperconnectivity in preclinical progranulin mutation carriers. NeuroImage: Clinical, 2019, 22, 101751.	1.4	30
280	Proposed research criteria for prodromal behavioural variant frontotemporal dementia. Brain, 2022, 145, 1079-1097.	3.7	30
281	Regional proton magnetic resonance spectroscopy patterns in dementia with Lewy bodies. Neurobiology of Aging, 2014, 35, 1483-1490.	1.5	29
282	A robust biomarker of largeâ€scale network failure in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 152-161.	1.2	29
283	Witnessed apneas are associated with elevated tau-PET levels in cognitively unimpaired elderly. Neurology, 2020, 94, e1793-e1802.	1.5	28
284	Absence of Rapid Eye Movement Sleep Behavior Disorder in 11 Members of the Pallidopontonigral Degeneration Kindred. Archives of Neurology, 2006, 63, 268.	4.9	27
285	Frequency and topography of cerebral microbleeds in dementia with Lewy bodies compared to Alzheimer's disease. Parkinsonism and Related Disorders, 2015, 21, 1101-1104.	1.1	27
286	Joint associations of Î <sup>2</sup> -amyloidosis and cortical thickness with cognition. Neurobiology of Aging, 2018, 65, 121-131.	1.5	27
287	Active lifestyles moderate clinical outcomes in autosomal dominant frontotemporal degeneration. Alzheimer's and Dementia, 2020, 16, 91-105.	0.4	27
288	Utility of FDG-PET in diagnosis of Alzheimer-related TDP-43 proteinopathy. Neurology, 2020, 95, e23-e34.	1.5	27

#	Article	IF	CITATIONS
289	Association of Initial Î <sup>2</sup> -Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment. JAMA Neurology, 2021, 78, 217.	4.5	27
290	FDG PET metabolic signatures distinguishing prodromal DLB and prodromal AD. NeuroImage: Clinical, 2021, 31, 102754.	1.4	27
291	Very Early Semantic Dementia With Progressive Temporal Lobe Atrophy. Archives of Neurology, 2008, 65, 1659-63.	4.9	26
292	Long-Term Exercise Training for an Individual With Mixed Corticobasal Degeneration and Progressive Supranuclear Palsy Features: 10-Year Case Report Follow-up. Physical Therapy, 2014, 94, 289-296.	1.1	26
293	<sup>18</sup> Fâ€AVâ€1451 uptake differs between dementia with lewy bodies and posterior cortical atrophy. Movement Disorders, 2019, 34, 344-352.	2.2	26
294	Dementia with Lewy bodies: association of Alzheimer pathology with functional connectivity networks. Brain, 2021, 144, 3212-3225.	3.7	26
295	Clinical Characterization of a Kindred With a Novel 12-Octapeptide Repeat Insertion in the Prion Protein Gene. Archives of Neurology, 2011, 68, 1165.	4.9	25
296	Normative and isolated rapid eye movement sleep without atonia in adults without REM sleep behavior disorder. Sleep, 2019, 42, .	0.6	25
297	REM sleep atonia loss distinguishes synucleinopathy in older adults with cognitive impairment. Neurology, 2020, 94, e15-e29.	1.5	25
298	MRS in Mild Cognitive Impairment: Early Differentiation of Dementia with Lewy Bodies and Alzheimer's Disease. Journal of Neuroimaging, 2015, 25, 269-274.	1.0	24
299	Tau-negative amnestic dementia masquerading as Alzheimer disease dementia. Neurology, 2018, 90, e940-e946.	1.5	24
300	Selecting software pipelines for change in flortaucipir SUVR: Balancing repeatability and group separation. NeuroImage, 2021, 238, 118259.	2.1	24
301	Clinical Features and Survival of 3R and 4R Tauopathies Presenting as Behavioral Variant Frontotemporal Dementia. Alzheimer Disease and Associated Disorders, 2007, 21, S39-S43.	0.6	23
302	Diabetes is Associated with Worse ExecutiveÂFunction in Both Eastern andÂWestern Populations: Shanghai Aging Study andÂMayo Clinic Study of Aging. Journal of Alzheimer's Disease, 2015, 47, 167-176.	1.2	23
303	Role of β-Amyloidosis and Neurodegeneration in Subsequent Imaging Changes in Mild Cognitive Impairment. JAMA Neurology, 2015, 72, 1475.	4.5	23
304	MAPT haplotype diversity in multiple system atrophy. Parkinsonism and Related Disorders, 2016, 30, 40-45.	1.1	23
305	Evaluating pathogenic dementia variants in posterior cortical atrophy. Neurobiology of Aging, 2016, 37, 38-44.	1.5	23
306	Autonomic dysfunction and phenoconversion in idiopathic REM sleep behavior disorder. Clinical Autonomic Research, 2020, 30, 207-213.	1.4	23

#	Article	IF	CITATIONS
307	Revised Self-Monitoring Scale. Neurology, 2020, 94, e2384-e2395.	1.5	23
308	Update on the Diagnosis and Management of Sleep Disturbances in Dementia. Sleep Medicine Clinics, 2008, 3, 347-360.	1.2	22
309	Greatest rapid eye movement sleep atonia loss in men and older age. Annals of Clinical and Translational Neurology, 2014, 1, 733-738.	1.7	22
310	Age and neurodegeneration imaging biomarkers in persons with Alzheimer disease dementia. Neurology, 2016, 87, 691-698.	1.5	22
311	Rates of lobar atrophy in asymptomatic <i>MAPT</i> mutation carriers. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 338-346.	1.8	22
312	Association of Longitudinal β-Amyloid Accumulation Determined by Positron Emission Tomography With Clinical and Cognitive Decline in Adults With Probable Lewy Body Dementia. JAMA Network Open, 2019, 2, e1916439.	2.8	22
313	MRI correlates of alien leg-like phenomenon in corticobasal degeneration. Movement Disorders, 2005, 20, 870-873.	2.2	21
314	Globular Glial Tauopathy Presenting as Semantic Variant Primary Progressive Aphasia. JAMA Neurology, 2016, 73, 123.	4.5	21
315	RAB39B gene mutations are not a common cause of Parkinson's disease or dementia with Lewy bodies. Neurobiology of Aging, 2016, 45, 107-108.	1.5	21
316	Brain volumetric deficits in <i>MAPT</i> mutation carriers: a multisite study. Annals of Clinical and Translational Neurology, 2021, 8, 95-110.	1.7	21
317	Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTD spectrum disorders. Cell Reports Medicine, 2022, 3, 100607.	3.3	21
318	A kinematic study of progressive apraxia with and without dementia. Movement Disorders, 1999, 14, 276-287.	2.2	20
319	Cognitive and behavioral features of c9FTD/ALS. Alzheimer's Research and Therapy, 2012, 4, 29.	3.0	20
320	Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum. Neurobiology of Aging, 2016, 46, 32-42.	1.5	20
321	Progranulin. Neurology, 2018, 90, 118-125.	1.5	20
322	Clinicopathologic discrepancies in a populationâ€based incidence study of parkinsonism in olmsted county: 1991â€2010. Movement Disorders, 2017, 32, 1439-1446.	2.2	19
323	Elevated medial temporal lobe and pervasive brain tauâ€PET signal in normal participants. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 210-216.	1.2	19
324	Linear vs volume measures of ventricle size. Neurology, 2020, 94, e549-e556.	1.5	19

#	Article	IF	CITATIONS
325	Rates of Brain Atrophy Across Disease Stages in Familial Frontotemporal Dementia Associated With MAPT, GRN, and C9orf72 Pathogenic Variants. JAMA Network Open, 2020, 3, e2022847.	2.8	19
326	Specialist approaches to prognostic counseling in isolated REM sleep behavior disorder. Sleep Medicine, 2021, 79, 107-112.	0.8	19
327	The temporal onset of the core features in dementia with Lewy bodies. Alzheimer's and Dementia, 2022, 18, 591-601.	0.4	19
328	<sup>1</sup> H-MRS metabolites and rate of β-amyloid accumulation on serial PET in clinically normal adults. Neurology, 2017, 89, 1391-1399.	1.5	18
329	Physician and patient determinants of prognostic counseling in idiopathic REM sleep-behavior disorder. Sleep Medicine, 2019, 62, 80-85.	0.8	18
330	Multimodal imaging in familial FTLD: phenoconversion and planning for the future. Brain, 2019, 142, 8-11.	3.7	18
331	Confirmation of <sup>123</sup> I-FP-CIT SPECT Quantification Methods in Dementia with Lewy Bodies and Other Neurodegenerative Disorders. Journal of Nuclear Medicine, 2020, 61, 1628-1635.	2.8	18
332	Effect of the Histone Deacetylase Inhibitor FRM-0334 on Progranulin Levels in Patients With Progranulin Gene Haploinsufficiency. JAMA Network Open, 2021, 4, e2125584.	2.8	18
333	Cerebrovascular disease, neurodegeneration, and clinical phenotype in dementia with Lewy bodies. Neurobiology of Aging, 2021, 105, 252-261.	1.5	18
334	Frontal lobe <sup>1</sup> H MR spectroscopy in asymptomatic and symptomatic <i>MAPT</i> mutation carriers. Neurology, 2019, 93, e758-e765.	1.5	18
335	Current and future management of the corticobasal syndrome and corticobasal degeneration. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 533-548.	1.0	17
336	Predicting the future in idiopathic rapid-eye movement sleep behaviour disorder. Lancet Neurology, The, 2010, 9, 1040-1042.	4.9	17
337	Characterization of a Family With c9FTD/ALS Associated With the GGGGCC Repeat Expansion in C9ORF72. Archives of Neurology, 2012, 69, 1164-9.	4.9	17
338	Transient Epileptic Amnesia: A Treatable Cause of Spells Associated With Persistent Cognitive Symptoms. Frontiers in Neurology, 2019, 10, 939.	1.1	17
339	18F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies. Brain Communications, 2020, 2, fcaa040.	1.5	17
340	MRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous. Annals of Clinical and Translational Neurology, 2020, 7, 707-721.	1.7	17
341	Long-read targeted sequencing uncovers clinicopathological associations for <i>C9orf72</i> -linked diseases. Brain, 2021, 144, 1082-1088.	3.7	17
342	Pick's disease: clinicopathologic characterization of 21 cases. Journal of Neurology, 2020, 267, 2697-2704.	1.8	17

#	Article	IF	CITATIONS
343	Implicit Learning of Sequential Regularities and Spatial Contexts in Corticobasal Syndrome. Neurocase, 2007, 13, 133-143.	0.2	16
344	Autoimmune dementia and encephalopathy. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 133, 247-267.	1.0	16
345	TREM2 p.R47H substitution is not associated with dementia with Lewy bodies. Neurology: Genetics, 2016, 2, e85.	0.9	16
346	Clinical, diagnostic, genetic and management issues in dementia with Lewy bodies. Clinical Science, 2005, 109, 343-354.	1.8	15
347	The GGGGCC Repeat Expansion inC9ORF72in a Case with Discordant Clinical and FDG-PET Findings: PET Trumps Syndrome. Neurocase, 2014, 20, 110-120.	0.2	15
348	Association Between Microinfarcts and Blood Pressure Trajectories. JAMA Neurology, 2018, 75, 212.	4.5	15
349	Longitudinal atrophy in prodromal dementia with Lewy bodies points to cholinergic degeneration. Brain Communications, 2022, 4, fcac013.	1.5	15
350	Clinical Phenomenology and Mortality in Charles Bonnet Syndrome. Journal of Geriatric Psychiatry and Neurology, 2013, 26, 3-9.	1.2	14
351	Genetic variants associated with susceptibility to psychosis inÂlate-onset Alzheimer's disease families. Neurobiology of Aging, 2015, 36, 3116.e9-3116.e16.	1.5	14
352	Submentalis Rapid Eye Movement Sleep Muscle Activity: A Potential Biomarker for Synucleinopathy. Annals of Neurology, 2019, 86, 969-974.	2.8	14
353	Tracking white matter degeneration in asymptomatic and symptomatic MAPT mutation carriers. Neurobiology of Aging, 2019, 83, 54-62.	1.5	14
354	Excessive Daytime Sleepiness in Major Dementia Syndromes. American Journal of Alzheimer's Disease and Other Dementias, 2019, 34, 261-264.	0.9	14
355	Trajectory of lobar atrophy in asymptomatic and symptomatic GRN mutation carriers: a longitudinal MRI study. Neurobiology of Aging, 2020, 88, 42-50.	1.5	14
356	Effect Modifiers of TDP-43-Associated Hippocampal Atrophy Rates in Patients with Alzheimer's Disease Neuropathological Changes. Journal of Alzheimer's Disease, 2020, 73, 1511-1523.	1.2	14
357	Frequency and distribution of TAR DNA-binding protein 43 (TDP-43) pathology increase linearly with age in a large cohort of older adults with and without dementia. Acta Neuropathologica, 2022, 144, 159-160.	3.9	14
358	Distinctive MRI findings in pallidopontonigral degeneration (PPND). Neurology, 2007, 68, 620-621.	1.5	13
359	Association between transactive response DNA-binding protein ofÂ43 kDa type and cognitive resilience to Alzheimer's disease: aÂcase-control study. Neurobiology of Aging, 2020, 92, 92-97.	1.5	13
360	Uniform data set language measures for bvFTD and PPA diagnosis and monitoring. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12148.	1.2	13

#	Article	IF	CITATIONS
361	β-Amyloid PET and <sup>123</sup> I-FP-CIT SPECT in Mild Cognitive Impairment at Risk for Lewy Body Dementia. Neurology, 2021, 96, .	1.5	13
362	MRI quantitative susceptibility mapping of the substantia nigra as an early biomarker for Lewy body disease. Journal of Neuroimaging, 2021, 31, 1020-1027.	1.0	13
363	Longitudinal anatomic, functional, and molecular characterization of Pick disease phenotypes. Neurology, 2020, 95, e3190-e3202.	1.5	13
364	ASLPrep: a platform for processing of arterial spin labeled MRI and quantification of regional brain perfusion. Nature Methods, 2022, 19, 683-686.	9.0	13
365	Corticobasal Degeneration. , 2005, , 309-334.		12
366	Abnormal expression of homeobox genes and transthyretin in <i>C9ORF72</i> expansion carriers. Neurology: Genetics, 2017, 3, e161.	0.9	12
367	Timeline of Rapid Eye Movement Sleep Behavior Disorder in Overt <scp>Alphaâ€<del>S</del>ynucleinopathies</scp> . Annals of Neurology, 2021, 89, 293-303.	2.8	12
368	Recognition memory and divergent cognitive profiles in prodromal genetic frontotemporal dementia. Cortex, 2021, 139, 99-115.	1.1	12
369	Posterior cortical atrophy phenotypic heterogeneity revealed by decoding 18F-FDG-PET. Brain Communications, 2021, 3, fcab182.	1.5	12
370	Novel Associations of <i>BST1</i> and <i>LAMP3</i> With REM Sleep Behavior Disorder. Neurology, 2021, 96, e1402-e1412.	1.5	12
371	Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium. Frontiers in Neurology, 2021, 12, 805135.	1.1	12
372	FTDPâ€17 with Pick bodyâ€like inclusions associated with a novel tau mutation, p.E372G. Brain Pathology, 2017, 27, 612-626.	2.1	11
373	Clinicopathological and <sup>123</sup> lâ€ <scp>FP</scp> â€ <scp>CIT SPECT</scp> correlations in patients with dementia. Annals of Clinical and Translational Neurology, 2018, 5, 376-381.	1.7	11
374	Incidence of frontotemporal disorders in Olmsted County: A populationâ€based study. Alzheimer's and Dementia, 2020, 16, 482-490.	0.4	11
375	The Cortical Basal ganglia Functional Scale (CBFS): Development and preliminary validation. Parkinsonism and Related Disorders, 2020, 79, 121-126.	1.1	11
376	Quality of life and caregiver burden in familial frontotemporal lobar degeneration: Analyses of symptomatic and asymptomatic individuals within the LEFFTDS cohort. Alzheimer's and Dementia, 2020, 16, 1115-1124.	0.4	11
377	Comprehensive Analysis of Familial Parkinsonism Genes in Rapidâ€Eyeâ€Movement Sleep Behavior Disorder. Movement Disorders, 2021, 36, 235-240.	2.2	11
378	The value of multimodal imaging with 123I-FP-CIT SPECT in differential diagnosis of dementia with Lewy bodies and Alzheimer's disease dementia. Neurobiology of Aging, 2021, 99, 11-18.	1.5	11

#	Article	IF	CITATIONS
379	<i>APOE</i> É <i>4</i> Allele Testing and Risk of Alzheimer Disease. JAMA - Journal of the American Medical Association, 2021, 325, 484.	3.8	11
380	Longitudinal Tau Positron Emission Tomography in Dementia with Lewy Bodies. Movement Disorders, 2022, 37, 1256-1264.	2.2	11
381	Objective sleep profile in LGI1/CASPR2 autoimmunity. Sleep, 2022, 45, .	0.6	11
382	Anatomy of disturbed sleep in pallidoâ€pontoâ€nigral degeneration. Annals of Neurology, 2011, 69, 1014-1025.	2.8	10
383	Is rapid eye movement sleep behavior disorder in Parkinson disease a specific disease subtype?. Sleep Medicine, 2013, 14, 931-933.	0.8	10
384	The influence of β-amyloid on [ <sup>18</sup> F]AV-1451 in semantic variant of primary progressive aphasia. Neurology, 2019, 92, e710-e722.	1.5	10
385	Cerebral Amyloid Angiopathy Pathology and Its Association With Amyloid-Î <sup>2</sup> PET Signal. Neurology, 2021, 97, e1799-e1808.	1.5	10
386	Steroid-responsive encephalopathy subsequently associated with Alzheimer's disease pathology: A case series. Neurocase, 2012, 18, 1-12.	0.2	9
387	Pittsburgh compound B (PiB) PET imaging of meningioma and other intracranial tumors. Journal of Neuro-Oncology, 2018, 136, 373-378.	1.4	9
388	Brain MR Spectroscopy Changes Precede Frontotemporal Lobar Degeneration Phenoconversion in Mapt Mutation Carriers. Journal of Neuroimaging, 2019, 29, 624-629.	1.0	9
389	Neuroprotection in idiopathic REM sleep behavior disorder: a role for exercise?. Sleep, 2019, 42, .	0.6	9
390	Lewy Body Dementia Association's Research Centers of Excellence Program: Inaugural Meeting Proceedings. Alzheimer's Research and Therapy, 2019, 11, 23.	3.0	9
391	CSF1R mutation presenting as dementia with Lewy bodies. Neurocase, 2019, 25, 17-20.	0.2	9
392	Outcome Measures for Dementia With Lewy Body Clinical Trials. Alzheimer Disease and Associated Disorders, 2021, Publish Ahead of Print, .	0.6	9
393	The contribution of behavioral features to caregiver burden in FTLD spectrum disorders. Alzheimer's and Dementia, 2022, 18, 1635-1649.	0.4	9
394	The National Institute on Aging Lateâ€Onset Alzheimer's Disease Family Based Study: A resource for genetic discovery. Alzheimer's and Dementia, 2022, 18, 1889-1897.	0.4	9
395	Association of ABI3 and PLCG2 missense variants with disease risk and neuropathology in Lewy body disease and progressive supranuclear palsy. Acta Neuropathologica Communications, 2020, 8, 172.	2.4	8
396	MAPT subhaplotypes in corticobasal degeneration: assessing associations with disease risk, severity of tau pathology, and clinical features. Acta Neuropathologica Communications, 2020, 8, 218.	2.4	8

#	Article	IF	CITATIONS
397	Cerebral Amyloid Angiopathy Burden and Cerebral Microbleeds: Pathological Evidence for Distinct Phenotypes. Journal of Alzheimer's Disease, 2021, 81, 113-122.	1.2	8
398	A Review of the Non-Alzheimer Dementias. Journal of Clinical Psychiatry, 2006, 67, 1985-2001.	1.1	8
399	Ramelteon for Idiopathic REM Sleep Behavior Disorder: Implications for Pathophysiology and Future Treatment Trials. Journal of Clinical Sleep Medicine, 2016, 12, 643-645.	1.4	8
400	Clinical and electrophysiologic variability in amyotrophic lateral sclerosis within a kindred harboring the <i>C9ORF72</i> repeat expansion. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 132-137.	1.1	7
401	Uptake of AV-1451 in meningiomas. Annals of Nuclear Medicine, 2017, 31, 736-743.	1.2	7
402	TAR DNA-Binding Protein 43 Is Associated with Rate of Memory, Functional and Global Cognitive Decline in the Decade Prior to Death. Journal of Alzheimer's Disease, 2021, 80, 683-693.	1.2	7
403	REM Sleep Behavior Disorder in Parkinson's Disease, Dementia with Lewy Bodies, and Multiple System Atrophy. , 0, , 383-398.		7
404	Phenotypic subtypes of progressive dysexecutive syndrome due to Alzheimer's disease: a series of clinical cases. Journal of Neurology, 2022, 269, 4110-4128.	1.8	7
405	Abnormal rapid eye movement sleep atonia control in chronic post-traumatic stress disorder. Sleep, 2022, 45, .	0.6	7
406	Neuropsychological Characterization of Evolving Cognitive Decline in Idiopathic REM Sleep Behavior Disorder Is Important, But Not Easy. Sleep, 2011, 34, 561-562.	0.6	6
407	Chiari 1 Malformation Presenting as Central Sleep Apnea during Pregnancy: A Case Report, Treatment Considerations, and Review of the Literature. Frontiers in Neurology, 2014, 5, 195.	1.1	6
408	A familial form of parkinsonism, dementia, and motor neuron disease: A longitudinal study. Parkinsonism and Related Disorders, 2014, 20, 1129-1134.	1.1	6
409	Neuromelanin-sensitive imaging in patients with idiopathic rapid eye movement sleep behaviour disorder. Brain, 2016, 139, 1005-1007.	3.7	6
410	Phenoconversion from probable rapid eye movement sleep behavior disorder to mild cognitive impairment to dementia in a populationâ€based sample. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 127-130.	1.2	6
411	Dementia with Lewy bodies research consortia: A global perspective from the ISTAART Lewy Body Dementias Professional Interest Area working group. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12235.	1.2	6
412	Poly (ADP-Ribose) and α–synuclein extracellular vesicles in patients with Parkinson disease: A possible biomarker of disease severity. PLoS ONE, 2022, 17, e0264446.	1.1	6
413	Shared brain transcriptomic signature in TDP-43 type A FTLD patients with or without <i>GRN</i> mutations. Brain, 2022, 145, 2472-2485.	3.7	6
414	Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations. Translational Neurodegeneration, 2022, 11, 24.	3.6	6

#	Article	IF	CITATIONS
415	Sleepiness in Cognitively Unimpaired Older Adults Is Associated With CSF Biomarkers of Inflammation and Axonal Integrity. Frontiers in Aging Neuroscience, 0, 14, .	1.7	6
416	Sleep disorders in neurodegenerative diseases other than Parkinson's disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2011, 99, 1011-1050.	1.0	5
417	Case Report: Early-Onset Behavioral Variant Frontotemporal Dementia in Patient With Retrotransposed Full-Length Transcript of Matrin-3 Variant 5. Frontiers in Neurology, 2020, 11, 600468.	1.1	5
418	Alzheimer's Disease and Other Dementias. , 2011, , 1038-1047.		5
419	2-30-01 Clinicopathologic heterogeneity in clinically- and/or pathologically-diagnosed cortical-basal ganglionic degeneration. Journal of the Neurological Sciences, 1997, 150, S109-S110.	0.3	4
420	An 81-year-old man with imbalance and memory impairment. Neurology, 2007, 68, 1147-1152.	1.5	4
421	The Degenerative Dementias. , 2007, , 699-733.		4
422	Neuropsychiatric features of dementia. , 2009, , 85-100.		4
423	Sleep in Parkinson's Disease and Dementia with Lewy Bodies. Advances in Biological Psychiatry, 2012, , 61-70.	0.2	4
424	Amyloid- and tau-PET imaging in a familial prion kindred. Neurology: Genetics, 2018, 4, e290.	0.9	4
425	Levodopa-induced dyskinesia in dementia with Lewy bodies and Parkinson disease with dementia. Neurology: Clinical Practice, 2020, 10, 156-161.	0.8	4
426	Longitudinal clinical, neuropsychological, and neuroimaging characterization of a kindred with a 12-octapeptide repeat insertion in <i>PRNP</i> : the next generation. Neurocase, 2020, 26, 211-219.	0.2	4
427	TDP-43 is associated with a reduced likelihood of rendering a clinical diagnosis of dementia with Lewy bodies in autopsy-confirmed cases of transitional/diffuse Lewy body disease. Journal of Neurology, 2020, 267, 1444-1453.	1.8	4
428	Alzheimer's Disease and Other Dementias. , 2005, , 853-862.		4
429	SMPD1 variants do not have a major role in rapid eye movement sleep behavior disorder. Neurobiology of Aging, 2020, 93, 142.e5-142.e7.	1.5	4
430	Association Between Plasma Biomarkers of Amyloid, Tau, and Neurodegeneration with Cerebral Microbleeds. Journal of Alzheimer's Disease, 2022, 87, 1537-1547.	1.2	4
431	DEMENTIA WITH LEWY BODIES. CONTINUUM Lifelong Learning in Neurology, 2004, 10, 81-112.	0.4	3
432	Progress on Progranulin. Archives of Neurology, 2010, 67, 145-7.	4.9	3

#	Article	IF	CITATIONS
433	Mild cognitive impairment in rapid eye movement sleep behavior disorder: a predictor of dementia?. Sleep Medicine, 2013, 14, 1041-1042.	0.8	3
434	Rapid Eye Movement Sleep Parasomnias. , 2017, , 993-1001.e6.		3
435	Clinical and Neuroimaging Aspects of Familial Frontotemporal Lobar Degeneration Associated with MAPT and GRN Mutations. Advances in Experimental Medicine and Biology, 2021, 1281, 77-92.	0.8	3
436	Alzheimer Disease and Other Dementias. , 2017, , 935-943.e6.		3
437	Evidence for cholinesterase-inhibitor therapy for dementia associated with Parkinson's disease. Lancet Neurology, The, 2005, 4, 137-8.	4.9	3
438	Rare PSAP Variants and Possible Interaction with CBA in REM Sleep Behavior Disorder. Journal of Parkinson's Disease, 2022, 12, 333-340.	1.5	3
439	TDP-43-associated atrophy in brains with and without frontotemporal lobar degeneration. NeuroImage: Clinical, 2022, 34, 102954.	1.4	3
440	Behavioral Variant Frontotemporal Dementia. CONTINUUM Lifelong Learning in Neurology, 2022, 28, 702-725.	0.4	3
441	Dementia with Lewy bodies. , 0, , 7-26.		2
442	Early clinical features of the parkinsonian-related dementias. , 0, , 197-212.		2
443	Dementia treatment. , 0, , 213-253.		2
444	ApoE and Quality of Life in Nonagenarians. Journal of the American Medical Directors Association, 2012, 13, 704-707.	1.2	2
445	Limb immobilization and corticobasal syndrome. Parkinsonism and Related Disorders, 2012, 18, 1097-1099.	1.1	2
446	Magnetic resonance elastography of frontotemporal dementia. Journal of Magnetic Resonance Imaging, 2016, 43, spcone.	1.9	2
447	Lewy Body Dementias. Focus (American Psychiatric Publishing), 2017, 15, 85-100.	0.4	2
448	Novel GRN mutation presenting as an aphasic dementia and evolving into corticobasal syndrome. Neurology: Genetics, 2017, 3, e201.	0.9	2
449	Tau Mutations as a Novel Risk Factor for Cancer—Letter. Cancer Research, 2018, 78, 6523-6524.	0.4	2
450	REM Sleep Behavior Disorder Associated with Dementia with Lewy Bodies. , 2019, , 67-76.		2

#	Article	IF	CITATIONS
451	Protocol for an observational cohort study identifying factors predicting accurately end of life in dementia with Lewy bodies and promoting quality end-of-life experiences: the PACE-DLB study. BMJ Open, 2021, 11, e047554.	0.8	2
452	<i>APOE</i> Allele Testing and Alzheimer Disease—Reply. JAMA - Journal of the American Medical Association, 2021, 325, 2211.	3.8	2
453	Letter on "Natural history of pure autonomic failure: A United States prospective cohortâ€, Annals of Neurology, 2017, 81, 910-910.	2.8	2
454	Persistent cauda equina syndrome following bilateral aortoiliac dissection as a complication of cardiac angiography. , 1997, 40, 377-379.		1
455	SLEEP AND NEURODEGENERATIVE DISORDERS. CONTINUUM Lifelong Learning in Neurology, 2007, 13, 201-224.	0.4	1
456	Mild cognitive impairment. , 2009, , 172-187.		1
457	Early clinical features of the parkinsonian-related dementias. , 0, , 245-277.		1
458	Sleep issues in dementia. , 2016, , 446-469.		1
459	Electroencephalogram findings in patients with posterior cortical atrophy. Neurologia I Neurochirurgia Polska, 2018, 52, 690-694.	0.6	1
460	Multimodal imaging in RBD — present and future. Nature Reviews Neurology, 2018, 14, 574-576.	4.9	1
461	Orthostatic Hypotension as a Prodromal Marker of α-Synucleinopathies—Reply. JAMA Neurology, 2018, 75, 1155.	4.5	1
462	Lewy Body Dementia Association's Industry Advisory Council: proceedings of the second annual meeting. Alzheimer's Research and Therapy, 2021, 13, 124.	3.0	1
463	Sleep, Cognitive Dysfunction, and Dementia. , 2015, , 285-300.		1
464	Cognition and driving ability in isolated and symptomatic REM sleep behavior disorder. Sleep, 2022, 45, .	0.6	1
465	DEMENTIA WITH LEWY BODIES. , 2004, , 911-926.		0
466	REM Sleep Behavior Disorder and REM-Related Parasomnias. , 2005, , 435-441.		0
467	IC-P-062: DATSCAN FINDINGS IN PATIENTS WITH REM SLEEP BEHAVIOR DISORDER AND/OR COGNITIVE IMPAIRMENT. , 2014, 10, P35-P35.		0
468	PL-04-02: COMPLEXITIES OF LEWY BODY DISEASE. , 2014, 10, P248-P248.		0

#	Article	IF	CITATIONS
469	O5-03-01: Longitudinal evaluation of familial frontotemporal dementia subjects (LEFFTDS): Subject characteristics, aims, and methodology. , 2015, 11, P318-P319.		0
470	A 76 Year-Old Woman with Sleep and Waking Stridor, Sleep Talking, Orthostatic Hypotension, and Imbalance. Journal of Clinical Sleep Medicine, 2016, 12, 143-145.	1.4	0
471	P3â€255: PET TAU Imaging with AVâ€1451 in Microtubuleâ€Associated Protein TAU ( <i>MAPT</i> ) Mutation Carriers Relative to Alzheimer'S Disease Dementia and Controls. Alzheimer's and Dementia, 2016, 12, P927.	0.4	0
472	ICâ€Pâ€180: PET TAU Imaging With AVâ€1451 in Microtubule Associated Protein TAU <i>(MAPT)</i> Mutation Carriers Relative to Alzheimer's Disease Dementia and Controls. Alzheimer's and Dementia, 2016, 12, P131.	0.4	0
473	A Young Man With Progressive Language Difficulty and Early-Onset Dementia. JAMA Neurology, 2016, 73, 595.	4.5	0
474	[P2–317]: PHENOCONVERSION FROM ASYMPTOMATIC TO MINIMALLY SYMPTOMATIC FTLD: PRELIMINARY DATA IN THE LEFFTDS COHORT. Alzheimer's and Dementia, 2017, 13, P739.	0.4	0
475	Rapid Eye Movement Sleep Behavior Disorder. , 2017, , 1069-1086.		0
476	The Lewy body dementias. , 0, , 278-300.		0
477	[P1–334]: CHARACTERIZATION OF THE CLINICAL AND NEUROIMAGING FEATURES OF PATIENTS WITH DEMENTIA WITH LEWY BODIES ASSOCIATED WITH VARIANTS IN GLUCOCEREBROSIDASE (GBA). Alzheimer's and Dementia, 2017, 13, P384.	0.4	0
478	Neuropsychiatry of dementia. , 0, , 9-18.		0
479	Genetic approaches to neurodegenerative disease. , 0, , 57-76.		0
480	The non-fluent/agrammatic variant of primary progressive aphasia. , 0, , 164-177.		0
481	Cognitive disorders of the very old. , 0, , 425-434.		0
482	O5â€03â€04: THE LEWY BODY DEMENTIA ASSOCIATION RESEARCH CENTERS OF EXCELLENCE PROGRAM: TOW/ OPTIMIZING CLINICAL CARE AND CLINICAL TRIAL INFRASTRUCTURE. Alzheimer's and Dementia, 2018, 14, P1646.	ARD 0.4	0
483	Studying the natural history of frontotemporal lobar degeneration (FTLD): The ARTFL LEFFTDS longitudinal FTLD (ALLFTD) protocol. Alzheimer's and Dementia, 2020, 16, e045482.	0.4	0
484	0787 Autonomic Dysfunction and Phenoconversion in Idiopathic/Isolated REM Sleep Behavior Disorder. Sleep, 2020, 43, A300-A300.	0.6	0
485	Sensitivity of the Social Behavior Observer Checklist to Early Symptoms of Patients With Frontotemporal Dementia. Neurology, 2022, , 10.1212/WNL.00000000000200582.	1.5	0
486	0268 Characterization of Neurodegenerative Disorder Subtypes Based on Non-REM Hypertonia and Sleep Spindle Duration. Sleep, 2022, 45, A121-A121.	0.6	0

#	Article	IF	CITATIONS
487	0266 Sleep Spindle-Duration: A Potential Biomarker for Neurodegenerative Disorder Phenotyping. Sleep, 2022, 45, A120-A120.	0.6	0
488	0269 Non-REM sleep Hypertonia in Parkinsonian-Spectrum Disorders. Sleep, 2022, 45, A121-A122.	0.6	0
489	0267 The Influence of Antidepressants on Non-REM Hypertonia. Sleep, 2022, 45, A120-A121.	0.6	Ο